| Similar Articles |
|---|
 |
The Motley Fool
June 18, 2008
Brian Lawler |
Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.   |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
April 11, 2011
Brian Orelli |
Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
December 28, 2010
Brian Orelli |
No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005. |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
July 31, 2008
Brian Lawler |
Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it? |
The Motley Fool
October 28, 2011
Brian Orelli |
Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever. |
The Motley Fool
August 4, 2010
Mac Greer |
One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan. |
The Motley Fool
October 24, 2008
Brian Orelli |
Elan's Approaching the Black Elan doesn't have positive cash flow yet, but it's getting closer, with revenue and expenses headed in the right direction. |
The Motley Fool
February 9, 2011
Brian Orelli |
Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years. |
The Motley Fool
February 22, 2007
Brian Lawler |
Too Much Aplomb From Elan Elan releases its 2006 financial results, and its future is not as rosy as seems. Investors, take note. |
The Motley Fool
October 10, 2011
Frank Vinluan |
TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment. |
The Motley Fool
July 30, 2007
Brian Lawler |
The Good and Bad of Elan Investors, any bet on Elan is primarily a bet on the outcomes of Tysabri and AAB-001. |
The Motley Fool
September 5, 2008
Brian Lawler |
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. |
The Motley Fool
February 8, 2005
Charly Travers |
Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company |
The Motley Fool
April 3, 2009
Brian Orelli |
Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware. |
The Motley Fool
May 26, 2011
Brian Orelli |
Intriguing, Potentially Lucrative, But Still Not Worth the Jump in Shares Elan sets up a drug development deal with Proteostasis. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade. |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
January 13, 2010
Brian Orelli |
JPMorgan Challenge: On the Cusp of Greatness Development-stage drugmaker Medivation has a partner and is ready for phase 3 data to roll in. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Chemistry World
August 14, 2012
Andrew Turley |
Elan spins off drug discovery Irish drug maker Elan is to spin off its drug discovery activities as an independent company of 80 employees -- just under half the Elan workforce -- called Neotope Biosciences. The new company will focus on chronic degenerative diseases. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
March 27, 2008
Brian Lawler |
A Little Bit of Cash for ArQule Development-stage drugmaker ArQule announces that it has received a milestone payment for discovery-stage drug work that it performed for partner Wyeth. |
The Motley Fool
August 30, 2007
Brian Orelli |
Forget What Your Drug Was Approved For Baxter stages a new trial for an old drug. |
The Motley Fool
June 18, 2007
Billy Fisher |
Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high. |
The Motley Fool
September 30, 2009
Brian Orelli |
More Questions Than Answers From Elan Things that make you go hmmm. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch. |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
The Motley Fool
June 29, 2007
Brian Orelli |
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. |
The Motley Fool
October 25, 2007
Brian Lawler |
Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation? |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
November 26, 2007
Brian Lawler |
Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note. |
The Motley Fool
February 11, 2010
Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
The Motley Fool
September 28, 2006
Brian Lawler |
Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
July 2, 2009
Brian Orelli |
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Waiting on Memory Pharmaceuticals The small-cap biotech is testing a treatment for Alzheimer's, but investors should stand by. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
The Motley Fool
April 23, 2008
Brian Orelli |
Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs. |
The Motley Fool
January 17, 2012
Brian Orelli |
You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
January 12, 2005
Charly Travers |
Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
